QT Vascular's drug-coated balloon trial exceeds patient enrolment goal

CATALIST-LISTED QT Vascular said on Tuesday that the clinical trial for its Chocolate® Touch drug-coated balloon in Europe and New Zealand has "substantially exceeded" its patient enrolment goal for Q4 2014.

This drug-coated balloon is used to treat patients with peripheral arterial disease, where clogged arteries limit blood flow to vital tissues and organs.

QT Vascular said that it expects to obtain CE marking regulatory approval for the product in the second half of 2015, which would allow it to market the product in the European Union.